Table 1 Demographic and clinical characteristics of the patients enrolled

Patients (n)

20

20

Age (years)

62.3 ± 9.1

61.5 ± 10.1

Female (%)

7 (35%)

6 (30%)

Dialysis vintage (years)

9.2 ± 4.8

6.7 ± 4.5

Antihypertensive drug users (%)

16 (80%)

9 (45%)

Antiplatelet/anticoagulant users (%)^a

14 (82%)

17 (100%)

Ejection fraction (%)^a

70.4 ± 5.2

60.7 ± 8.0

 Ischemic heart disease (%)^a

7 (41%)

12 (71%)

 Heart failure (%)^a

6 (35%)

5 (29%)

 Cerebral infarction (%)^a

3 (18%)

2 (12%)

 Cerebral hemorrhage (%)^a

0 (0%)

1 (6%)

BMI (kg/m²)

24.0 ± 5.0

24.9 ± 4.3

White blood cell count (×10³/μL)

6.3 ± 1.8

6.6 ± 2.7

Hemoglobin (g/dL)

11.2 ± 0.8

11.0 ± 2.6

Platelet (×10⁴/μL)

20.0 ± 5.2

18.5 ± 4.9

ESA user (%)

13 (65%)

10 (50%)

Ferritin (ng/mL)

122.4 ± 141.4

94.2 ± 53.8

Phosphate (mg/dL)

5.6 ± 1.5

5.4 ± 1.6

Calcium (mg/dL)

9.1 ± 0.7

8.8 ± 0.6

Intact PTH (ng/mL)

122 ± 98

162 ± 163

Albumin (g/dL)

3.5 ± 0.3

3.5 ± 0.3

Total-cholesterol (mg/dL)

171 ± 36

154 ± 28

Triglyceride (mg/dL)

124 ± 70

142 ± 86

HDL-cholesterol (mg/dL)

44 ± 14

44 ± 15

Ankle brachial index (left)

1.11 ± 0.19

1.12 ± 0.26

Homocysteine (nmol/mL)

35.8 ± 25.1

34.7 ± 18.5

Pentosidine (μg/mL)

0.415 ± 0.218

0.326 ± 0.108

hsCRP (mg/dL)

0.221 ± 0.174

0.187 ± 0.196

Pentraxin 3 (ng/mL)

4.04 ± 1.68

4.55 ± 3.76

Adrenaline (ng/mL)

0.02 ± 0.01

0.02 ± 0.01

Noradrenaline(ng/mL)

0.33 ± 0.19

0.38 ± 0.19

Dopamine (ng/mL)

0.04 ± 0.02

0.05 ± 0.02